GlassScriptPhysician profile
Joseph Anthony Sferrazza
NPI 1700474509
$6,385.72
in general payments reported to CMS, 2019-2025
28 companies · $78.96 in 2025
The $78.96 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,073 · 2022: $2,560 · 2023: $1,503 · 2024: $1,170 · 2025: $78.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,752.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $748.13 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $695.68 | 2021-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $597.43 | 2022-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.26 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $533.03 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $485.73 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $350.45 | 2021-2024 | Farxiga, Lokelma |
| Amgen INC. | $348.28 | 2021-2024 | Repatha |
| Medtronic, INC. | $299.38 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $283.22 | 2021-2024 | Verquvo |
| Heartflow, INC. | $197.16 | 2022-2024 | |
| Esperion Therapeutics, INC. | $196.40 | 2021-2024 | Nexletol |
| Daiichi Sankyo INC. | $183.86 | 2022-2024 | Injectafer |
| Bardy Diagnostics, INC. | $140.72 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $123.69 | 2021 | |
| Novo Nordisk INC | $122.60 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Organogenesis INC. | $78.96 | 2025 | Via Matrix |
| Pfizer INC. | $75.39 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $56.01 | 2023-2024 | Evkeeza |
| Cvrx, INC. | $33.82 | 2024 | Barostim Neo System |
| Medicomp INC | $28.16 | 2023 | Telepatch Cardiac Monitor |
| Tactile Systems Technology INC | $23.17 | 2023 | Flexitouch Plus, Entre Plus |
| Atricure, INC. | $22.27 | 2024 | |
| Arbor Pharmaceuticals, INC. | $21.90 | 2021 | |
| Amarin Pharma, INC. | $21.24 | 2021 | |
| Astellas Pharma US INC | $19.84 | 2022 | |
| Abiomed | $17.94 | 2023 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sferrazza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.